Skip Navigation



European Heart Journal Advance Access published online on March 10, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi159
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
26/12/1188    most recent
ehi159v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Siminiak, T.
Right arrow Articles by Kurpisz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Siminiak, T.
Right arrow Articles by Kurpisz, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

European Heart Journal © The European Society of Cardiology 2005; all rights reserved
Received August 2, 2004
Revised December 30, 2004
Accepted January 6, 2005

Clinical research

Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial

Tomasz Siminiak 1*, Dorota Fiszer 2, Olga Jerzykowska 1, Beata Grygielska 2, Natalia Rozwadowska 2, Piotr Kalmucki 1, and Maciej Kurpisz 2

1 University School of Medical Sciences, Department of Cardiology, District Hospital, ul. Juraszow 7/19, PL 60-479, Poznan, Poland
2 Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland

* To whom correspondence should be addressed.
Tomasz Siminiak, E-mail: tomasz.siminiak{at}usoms.poznan.pl


  Abstract

Aims Several experimental studies and the initial clinical experience have shown that autologous skeletal myoblast transplantation into the area of post-infarction left ventricular injury results in an increase in segmental contractile performance. This phase I clinical trial was designed to assess the feasibility and safety of autologous skeletal myoblast transplantation performed via a percutaneous trans-coronary-venous approach in patients with post-infarction left ventricular dysfunction.

Methods and results Ten patients with heart failure and presence of an akinetic or a dyskinetic post-infarction injury with no viable myocardium were included in the study. Skeletal myoblasts were obtained from a biopsy specimen and grown in cell culture. Patients were treated with prophylactic amiodarone infusion before and during the procedure, except one patient. Skeletal myoblast transplantations were performed uneventfully in nine patients using the TransAccess® catheter system under fluoroscopic and intravascular ultrasound guidance. In one patient, the procedure was not performed because of the inability of appropriate coronary sinus guiding wire positioning across venous valve. In five patients, the anterior interventricular vein and in four patients, the middle cardiac vein were used to access the myocardium. Two to four intramyocardial injections 1.5-4.5 cm deep were performed in each patient, delivering up to 100 million cells in 0.4-2.5 mL of saline. During 6 months follow-up, New York Heart Association class improved in all patients and ejection fraction increased 3-8% in six out of nine cases.

Conclusion These data suggest the feasibility and procedural safety of myoblast transplantation performed via the trans-coronary-venous approach using the TransAccess catheter system.

Keywords: Myocytes; Heart failure; Cells; Catheters; Myocardial infarction.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur. J. Cardiothorac. Surg.Home page
A. R. Akar, S. Durdu, M. Arat, M. Kilickap, N. O. Kucuk, O. Arslan, I. Kuzu, and U. Ozyurda
Five-year follow-up after transepicardial implantation of autologous bone marrow mononuclear cells to ungraftable coronary territories for patients with ischaemic cardiomyopathy
Eur. J. Cardiothorac. Surg., October 1, 2009; 36(4): 633 - 643.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
B. J. Gersh, R. D. Simari, A. Behfar, C. M. Terzic, and A. Terzic
Cardiac Cell Repair Therapy: A Clinical Perspective
Mayo Clin. Proc., October 1, 2009; 84(10): 876 - 892.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Menasche
Stem Cell Therapy for Heart Failure: Are Arrhythmias a Real Safety Concern?
Circulation, May 26, 2009; 119(20): 2735 - 2740.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
E. Macia and P. A. Boyden
Stem Cell Therapy Is Proarrhythmic
Circulation, April 7, 2009; 119(13): 1814 - 1823.
[Full Text] [PDF]

Home page
 CirculationHome page
H. Q. Ly and S. Nattel
Stem Cells Are Not Proarrhythmic: Letting the Genie out of the Bottle
Circulation, April 7, 2009; 119(13): 1824 - 1831.
[Full Text] [PDF]

Home page
 J Am Coll Cardiol IntvHome page
N. Dib, J. Dinsmore, Z. Lababidi, B. White, S. Moravec, A. Campbell, A. Rosenbaum, K. Seyedmadani, W. A. Jaber, C. S. Rizenhour, et al.
One-Year Follow-Up of Feasibility and Safety of the First U.S., Randomized, Controlled Study Using 3-Dimensional Guided Catheter-Based Delivery of Autologous Skeletal Myoblasts for Ischemic Cardiomyopathy (CAuSMIC Study)
J. Am. Coll. Cardiol. Intv., January 1, 2009; 2(1): 9 - 16.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Menasche, O. Alfieri, S. Janssens, W. McKenna, H. Reichenspurner, L. Trinquart, J.-T. Vilquin, J.-P. Marolleau, B. Seymour, J. Larghero, et al.
The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) Trial: First Randomized Placebo-Controlled Study of Myoblast Transplantation
Circulation, March 4, 2008; 117(9): 1189 - 1200.
[Abstract] [Full Text] [PDF]

Home page
 pdiHome page
A. G. Zenovich and D. A. Taylor
CELL THERAPY IN KIDNEY DISEASE: CAUTIOUS OPTIMISM... BUT OPTIMISM NONETHELESS
Perit. Dial. Int., June 1, 2007; 27(Supplement_2): S94 - S103.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
M. A. Retuerto, J. T. Beckmann, J. Carbray, G. Patejunas, S. Sarateanu, B. J. Kane, B. Smulevitz, D. D. McPherson, and T. K. Rosengart
Angiogenic pretreatment to enhance myocardial function after cellular cardiomyoplasty with skeletal myoblasts
J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 478 - 484.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
T. Siminiak, E. Meliga, O. Jerzykowska, and P. W. Serruys
Percutaneous transplantation of skeletal myoblast in the treatment of post-infarction injury
Eur. Heart J. Suppl., December 1, 2006; 8(suppl_H): H57 - H64.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
I. Ben-Dor, S. Fuchs, and R. Kornowski
Potential Hazards and Technical Considerations Associated With Myocardial Cell Transplantation Protocols for Ischemic Myocardial Syndrome
J. Am. Coll. Cardiol., October 17, 2006; 48(8): 1519 - 1526.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
O. Caspi and L. Gepstein
Stem cells for myocardial repair
Eur. Heart J. Suppl., September 1, 2006; 8(suppl_E): E43 - E54.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
A. J. Boyle, S. P. Schulman, and J. M. Hare
Stem Cell Therapy for Cardiac Repair: Ready for the Next Step
Circulation, July 25, 2006; 114(4): 339 - 352.
[Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2125 - 2133.
[Full Text] [PDF]

Home page
 Eur. J. Cardiothorac. Surg.Home page
I. Dimarakis, N. A. Habib, and M. Y.A. Gordon
Adult bone marrow-derived stem cells and the injured heart: just the beginning?
Eur. J. Cardiothorac. Surg., November 1, 2005; 28(5): 665 - 676.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.